# CHANGELOG

## Final Test 3 — Drug Safety Evidence Integration Capability

### Current Implementation Updates

#### 1. Current-State Audit
- Reviewed the existing Drug Safety / QC evidence-processing capability.
- Identified implemented, documented, partial, missing, and test-required areas.
- Preserved existing project components rather than restarting the implementation.

#### 2. Canonical Evidence Schema
- Established the canonical evidence structure.
- Preserved separation between observation, interpretation, evidence quality, validation state, and human-review state.
- Added source and provenance fields required for traceability.

#### 3. Evidence Normalization
- Added/verified deterministic evidence normalization.
- Structured incoming evidence into the canonical representation.
- Preserved relevant source and evidence identifiers.

#### 4. Drug / Product Matching
- Added deterministic drug/product matching.
- Supports exact matching and unmatched cases.
- Prevents unsafe silent identity matching such as treating `Drug A` as `Drug AB`.
- Ambiguous or unmatched cases can be routed for review.

#### 5. Duplicate Detection
- Added duplicate evidence detection.
- Duplicate identification follows deterministic implemented rules.
- Original evidence records are preserved.

#### 6. Conflict Detection
- Added conflict detection for explicitly opposing evidence observations.
- Conflicting records are preserved rather than silently removed.
- Conflict detection is intentionally conservative.

#### 7. Evidence Validation
- Added structural evidence validation.
- Required-field and data-quality conditions are checked.
- Validation results are kept separate from clinical interpretation.

#### 8. Human Review
- Added human-review flagging.
- Review flags identify records or conditions requiring additional review.
- Human-review flags do not establish clinical safety, causality, or regulatory significance.

#### 9. Automated Testing
- Implemented and executed the required TEST-01 through TEST-12 scenarios.
- Tests cover validation, matching, duplicate detection, conflict detection, human-review behavior, and integration behavior.
- Test outcomes are documented in `TEST_RESULTS.md`.

#### 10. Structured Output
- Added structured evidence output.
- Output is designed to preserve evidence identifiers and provenance.
- Deterministic processing supports reproducibility and replay.

#### 11. Evidence Packet
- Created `evidence_packet/`.
- Added `evidence_packet/code_packet/`.
- Added the critical implementation files to the code packet.
- Added `CODE_PACKET_INDEX.md` to describe the review relevance of each file.
- Created `evidence_packet/screenshots/` for runtime evidence collection.

#### 12. Handover Documentation
- Added `HANDOVER.md`.
- Documented implementation scope, execution flow, testing, limitations, and reviewer guidance.

---

## Current Status

The core Drug Safety Evidence Integration capability has been implemented and tested within the current project environment.

Remaining final packaging activities include runtime screenshots, final evidence-packet completion, final requirement audit, and submission verification.

---

## Important Boundaries

The implementation does not:

- perform clinical diagnosis;
- automatically determine adverse drug reaction causality;
- make regulatory decisions;
- create fake evidence;
- silently delete conflicting evidence;
- replace qualified human review.

Structural validation and evidence-processing flags should not be interpreted as clinical or regulatory conclusions.